Home » Stocks » ADVM

Adverum Biotechnologies, Inc. (ADVM)

Stock Price: $13.39 USD -0.03 (-0.22%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $13.26 -0.13 (-0.97%) Jan 22, 5:35 PM
Market Cap 1.31B
Revenue (ttm) n/a
Net Income (ttm) -98.80M
Shares Out 88.87M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $13.39
Previous Close $13.42
Change ($) -0.03
Change (%) -0.22%
Day's Open 13.46
Day's Range 13.05 - 13.57
Day's Volume 647,338
52-Week Range 7.98 - 25.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Forbes - 20 hours ago

Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclos...

Zacks Investment Research - 1 week ago

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 2 weeks ago

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

GlobeNewsWire - 2 weeks ago

-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites...

GlobeNewsWire - 1 month ago

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare dis...

GlobeNewsWire - 2 months ago

-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after  a single IVT injection of ADVM-022 -- -- R obust preliminary aqueous a nti-VEGF protein expression observed at 18 m...

Zacks Investment Research - 2 months ago

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 11.43% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead...

GlobeNewsWire - 3 months ago

-- Dr. Carl Regillo to present OPTIC data a t the R etina S ubspecialty D ay on  Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday , No...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

Seeking Alpha - 3 months ago

Today, we take an in-depth look at Adverum Biotechnologies which has dropped by more than half from highs earlier this year.

GlobeNewsWire - 4 months ago

REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rar...

GlobeNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...

Zacks Investment Research - 5 months ago

Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare di...

GlobeNewsWire - 5 months ago

REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare di...

Seeking Alpha - 5 months ago

Adverum Biotechnologies, Inc. (ADVM) CEO Laurent Fischer on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for...

GlobeNewsWire - 5 months ago

REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...

GlobeNewsWire - 6 months ago

REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...

GlobeNewsWire - 6 months ago

-- INFINITY trial is currently enrolling patients with DME, the most common cause of vision loss in people with diabetic retinopathy -- REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE)...

GlobeNewsWire - 6 months ago

-- Patients in Cohort 4 received ADVM-022 high dose 6x1011 vg and prophylactic steroid eye drops -- -- Data from all four cohorts planned by the end of 2020 --

GlobeNewsWire - 6 months ago

-- Plans underway to begin expansion of manufacturing capabilities -- REDWOOD CITY, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stag...

GlobeNewsWire - 7 months ago

-- Laurent Fischer, M.D. joins as CEO -- -- Leone Patterson will continue to serve as president -- REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (...

Seeking Alpha - 7 months ago

The Wet AMD Gene Therapy Race - Adverum Biotechnologies Vs. Regenxbio

Other stocks mentioned: RGNX
Seeking Alpha - 7 months ago

Adverum Biotechnologies, Inc. (ADVM) CEO Leone Patterson on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -14.81% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead fo...

Zacks Investment Research - 7 months ago

Is (ADVM) Outperforming Other Medical Stocks This Year?

The Motley Fool - 8 months ago

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

Other stocks mentioned: ABBV, HRTX
Zacks Investment Research - 8 months ago

Is (ADVM) Outperforming Other Medical Stocks This Year?

The Motley Fool - 8 months ago

The company's experimental gene therapy for a common cause of blindness showed promise in a clinical trial.

Investors Business Daily - 8 months ago

Adverum Biotechnologies said Tuesday the effect of its gene therapy on an eye disease lasted for more than a year in a Phase 1 test of six patients — prodding Adverum stock to rocket. The pos...

The Motley Fool - 8 months ago

Adverum's lead gene therapy candidate continues to impress in its early-stage trial.

GlobeNewsWire - 8 months ago

-- Robust efficacy and evidence of a dose response from single intravitreal injection (IVT) of ADVM-022 -- -- Long-term durability beyond 1 year from single IVT injection of ADVM-022 with ...

Zacks Investment Research - 8 months ago

Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 8 months ago

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 9 months ago

REDWOOD CITY, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare ...

Zacks Investment Research - 9 months ago

Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Zacks Investment Research - 10 months ago

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 10 months ago

Adverum Biotechnologies, Inc. (ADVM) CEO Leone Patterson on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 6.45% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead f...

Zacks Investment Research - 10 months ago

Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 10 months ago

Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 10 months ago

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...

GlobeNewsWire - 11 months ago

REDWOOD CITY, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...

Benzinga - 11 months ago

Adverum Biotechnologies Inc (NASDAQ: ADVM) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-relate...

The Motley Fool - 11 months ago

Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.

GlobeNewsWire - 11 months ago

-- Robust efficacy with evidence of a dose response -- -- 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks --  -- 4/6 patients rescue-injection-free in cohort 2 (l...

GlobeNewsWire - 11 months ago

- New headquarters includes 80,000 square feet of office, laboratory, and manufacturing space to advance the development of Adverum’s novel gene therapies -

Seeking Alpha - 1 year ago

Adverum Biotechnologies: Keep On Your Watchlist In 2020

GlobeNewsWire - 1 year ago

-- OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20 -- -- IND application planned for ADVM-022 in diabetic reti...

About ADVM

Adverum Biotechnologies, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaborat... [Read more...]

Industry
Biotechnology
IPO Date
Jul 31, 2014
CEO
Leone Patterson
Employees
114
Stock Exchange
NASDAQ
Ticker Symbol
ADVM
Full Company Profile

Financial Performance

In 2019, ADVM's revenue was $250,000, a decrease of -84.49% compared to the previous year's $1.61 million. Losses were -$64.49 million, -11.21% less than in 2018.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is 25.22, which is an increase of 88.35% from the latest price.

Price Target
$25.22
(88.35% upside)
Analyst Consensus: Buy